Abbott’s Burton shares neuromodulation breakthroughs in diabetic peripheral neuropathy, chronic pain
In the newest episode of AbbottTalks, Allen Burton, Divisional VP and Chief Medical Officer of Neuromodulation at Abbott, shares insights into the company’s innovative neuromodulation therapies.
Burton delves into Abbott’s FDA-approved treatment for chronic back pain, which uses electrical stimulation to alleviate pain, improve functionality, and reduce reliance on opioids.
Burton discusses Abbott’s recent FDA approval to treat people who suffer from back pain with limited surgical options. He also expands on how the company’s pioneering treatment for painful diabetic peripheral neuropathy, a condition affecting millions of Americans. This treatment uses electrical stimulation to dampen painful signals in the feet, enabling patients to regain mobility and control over their lives. Burton further introduces the Eterna SCS System, the smallest neurostimulation system in the market, which offers patients a low charging burden and indications for MRI compatibility.
Listen to the full episode to hear directly from Abbott’s Neuromodulation CMO on how Abbott’s patient-centric neuromodulation therapies are impacting the lives of patients suffering from chronic pain and diabetic peripheral neuropathy.
Thank you to Resonant Link for sponsoring this episode of AbbottTalks. For more information about Resonant Link go to www.Resonant-Link.com.
Thank you for listening to the AbbottTalks Podcast.